tiprankstipranks
Trending News
More News >
Travere Therapeutics (TVTX)
NASDAQ:TVTX

Travere Therapeutics (TVTX) AI Stock Analysis

Compare
487 Followers

Top Page

TV

Travere Therapeutics

(NASDAQ:TVTX)

Rating:52Neutral
Price Target:
$17.00
▲( 7.32% Upside)
Travere Therapeutics demonstrates significant growth potential with strong sales performance and regulatory advancements for FILSPARI. However, the company's high leverage, sustained losses, and challenging valuation metrics pose financial risks. Technical indicators are mixed, and while the earnings call and corporate events provide positive signals, overall financial instability and competitive pressures temper the outlook, leading to a cautious score.
Positive Factors
Financial Performance
Filspari's Q1 revenue was in line with consensus at $56MM, showing 13% quarter-over-quarter growth, maintaining momentum from an impressive Q4.
Market Opportunity
The large upside with FSGS approval is seen as a significant opportunity for TVTX, with competitors being at least 2-3 years behind.
Regulatory Progress
The FDA accepted the supplemental New Drug Application for Filspari for the treatment of focal segmental glomerulosclerosis.
Negative Factors
Regulatory Concerns
The standard review timeline and intention to hold an AdCom can be perceived negatively, as it reflects FDA's cautiousness and potential resource issues.
Regulatory Uncertainty
Investors never like AdCom meetings, as they introduce some regulatory uncertainty.

Travere Therapeutics (TVTX) vs. SPDR S&P 500 ETF (SPY)

Travere Therapeutics Business Overview & Revenue Model

Company DescriptionTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
How the Company Makes MoneyTravere Therapeutics generates revenue primarily through the sale of its commercial products, which include FDA-approved therapies for rare diseases. The company's revenue model involves the commercialization of these therapies, which are often priced at a premium due to their specialized nature and the small patient populations they serve. Travere also engages in strategic partnerships and collaborations with other pharmaceutical companies, which can provide additional revenue streams through milestone payments, royalties, and licensing agreements. These partnerships can be crucial for expanding the company's reach and enhancing its research and development capabilities. Key factors contributing to Travere's earnings include successful product launches, the expansion of its product portfolio, and the ability to navigate regulatory pathways effectively to bring new therapies to market.

Travere Therapeutics Financial Statement Overview

Summary
Travere Therapeutics is experiencing growth in revenue, but profitability remains a significant challenge with continuous losses. The high debt levels and decreasing equity raise concerns about financial stability. Cash flow improvements are noted, but reliance on external financing remains high. Overall, the company exhibits a mixed financial outlook with potential risks associated with high leverage and sustained losses.
Income Statement
45
Neutral
Travere Therapeutics has shown a consistent increase in total revenue, particularly in the TTM period with a growth of 17% from the previous year. However, the company continues to operate at a loss with a negative net profit margin of -82.9% in TTM, indicating significant profitability challenges. Negative EBIT and EBITDA margins further highlight the ongoing operational inefficiencies.
Balance Sheet
40
Negative
The company's financial structure shows high leverage with a debt-to-equity ratio of 12.20 in the TTM, reflecting potential financial risk. Stockholders' equity has decreased significantly, leading to a low equity ratio of 5.98% in TTM. These factors pose concerns about financial stability in the long term.
Cash Flow
50
Neutral
Operating cash flow has improved in the TTM compared to the previous year, but remains negative, indicating cash flow challenges. The free cash flow has also improved but is still negative, showing the company is not generating sufficient cash to cover expenses. There is a positive trend in cash flow from financing activities, which suggests reliance on external funding.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
273.53M233.18M145.24M212.02M227.49M198.32M
Gross Profit
252.27M225.43M133.79M204.43M220.71M192.19M
EBIT
-223.77M-320.63M-376.74M-251.56M-139.50M-75.38M
EBITDA
-168.21M-265.77M-326.25M-299.42M-186.68M-143.95M
Net Income Common Stockholders
-226.71M-321.55M-111.40M-278.48M-180.09M-169.43M
Balance SheetCash, Cash Equivalents and Short-Term Investments
322.24M370.70M566.85M450.25M552.88M361.59M
Total Assets
548.80M594.13M788.91M672.59M776.63M607.44M
Total Debt
400.46M401.58M404.78M407.49M261.99M215.34M
Net Debt
338.57M343.05M346.61M345.80M96.23M130.57M
Total Liabilities
515.98M535.05M588.10M629.73M474.52M396.23M
Stockholders Equity
32.82M59.08M200.81M42.85M302.11M211.21M
Cash FlowFree Cash Flow
-175.26M-338.69M-322.28M-214.85M-38.94M-162.59M
Operating Cash Flow
-160.66M-237.47M-280.02M-186.29M-14.79M-42.74M
Investing Cash Flow
35.72M99.33M55.78M-32.55M-137.62M-61.33M
Financing Cash Flow
143.66M139.42M218.75M117.57M231.68M127.71M

Travere Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price15.84
Price Trends
50DMA
18.27
Negative
100DMA
19.22
Negative
200DMA
17.22
Negative
Market Momentum
MACD
-0.46
Positive
RSI
37.13
Neutral
STOCH
4.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVTX, the sentiment is Negative. The current price of 15.84 is below the 20-day moving average (MA) of 19.42, below the 50-day MA of 18.27, and below the 200-day MA of 17.22, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 37.13 is Neutral, neither overbought nor oversold. The STOCH value of 4.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TVTX.

Travere Therapeutics Risk Analysis

Travere Therapeutics disclosed 58 risk factors in its most recent earnings report. Travere Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We may not receive some or all of the potential milestone and/or royalty payments from our corporate and licensing transactions. Q4, 2024
2.
Guidelines and recommendations published by various organizations may impact the use of our products. Q4, 2024

Travere Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$2.22B18.68%41.67%75.79%
63
Neutral
$1.56B-5.78%25.50%64.63%
53
Neutral
$5.14B3.03-44.09%2.83%16.75%-0.06%
52
Neutral
$1.41B-422.66%49.29%44.52%
49
Neutral
$1.94B-16.57%
43
Neutral
$1.64B-23.34%-14.19%
39
Underperform
$1.25B-39.49%-20.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TVTX
Travere Therapeutics
15.84
9.08
134.32%
BCRX
BioCryst
10.59
4.40
71.08%
IRON
Disc Medicine
47.37
12.71
36.67%
IMCR
Immunocore Holdings
31.16
-15.14
-32.70%
VERA
Vera Therapeutics
19.64
-17.49
-47.10%
CGON
CG Oncology, Inc.
25.44
-6.99
-21.55%

Travere Therapeutics Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q1-2025)
|
% Change Since: -23.70%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant growth in FILSPARI sales and expansion approvals in Europe and the UK. The anticipation of approval for a new indication in FSGS is promising. However, financial challenges such as higher gross to net discounts and anticipated generic competition for Thiola present concerns. Despite the net loss, the company's financial performance showed improvement over the previous year.
Q1-2025 Updates
Positive Updates
FILSPARI Sales and Growth
Net sales for FILSPARI grew 182% year-over-year and 13% versus the prior quarter, reflecting strong demand and uptake. The drug achieved $56 million in net product sales in the first quarter.
European and UK Approval for FILSPARI
The European Commission and MHRA in the UK converted FILSPARI's conditional approvals to full approvals for the treatment of adults with IgA nephropathy.
sNDA Submission for FSGS
The company completed its submission for an sNDA for FILSPARI for the FSGS indication in March, expecting potential approval as early as September, marking a historic milestone as the first approved medication for FSGS.
Strong Financial Performance
The company generated net product sales of $75.9 million in the first quarter, representing 90% growth over the same period last year.
Negative Updates
Higher Gross to Net Discounts
FILSPARI experienced higher gross to net discounts due to insurance coverage changes and the implementation of the Part D redesign, which will maintain higher discounts throughout the year compared to the previous year.
Anticipated Generic Competition for Thiola
The company anticipates more generic competition for Thiola and Thiola EC in the coming quarters, which could impact sales.
Continued Net Loss
The company reported a net loss for the first quarter of 2025 of $41.2 million or $0.47 per basic share, although this was an improvement compared to the same period in 2024.
Company Guidance
During the Travere Therapeutics Q1 2025 earnings call, the company provided several key metrics showcasing strong performance and strategic progress. FILSPARI's net sales grew by 182% year-over-year and 13% quarter-over-quarter, reaching approximately $56 million in Q1 2025. Travere received 703 new patient start forms in the quarter, indicating robust demand. The company anticipates potential FDA approval for FILSPARI in FSGS by September, which could open a market of up to 30,000 addressable patients. Additionally, Travere reported total revenues of $81.7 million for the quarter, with a net loss of $41.2 million, or $0.47 per share. The company ended Q1 with $322.2 million in cash and marketable securities, bolstered by expected milestone payments from partners. Travere also highlighted the upcoming PDUFA date of August 28 for a submission to modify FILSPARI's REMS program, which could further enhance product convenience and patient access.

Travere Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Travere Therapeutics Holds Annual Meeting, Elects Directors
Neutral
May 16, 2025

On May 15, 2025, Travere Therapeutics held its Annual Meeting where stockholders voted on several proposals. The company elected ten directors to serve until the 2026 Annual Meeting, approved an amendment to increase shares under the 2018 Equity Incentive Plan, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and strategic planning efforts.

The most recent analyst rating on (TVTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.

Product-Related AnnouncementsRegulatory Filings and Compliance
Travere Therapeutics’ FDA Acceptance for FILSPARI Application
Positive
May 15, 2025

On May 15, 2025, Travere Therapeutics announced that the FDA accepted its supplemental New Drug Application for FILSPARI® (sparsentan) for treating focal segmental glomerulosclerosis (FSGS), with a target action date set for January 13, 2026. If approved, FILSPARI could become the first FDA-approved treatment for FSGS, a rare kidney disorder affecting over 40,000 patients in the U.S. The application is supported by the Phase 3 DUPLEX Study and Phase 2 DUET Study, which demonstrated significant benefits in reducing proteinuria and improving remission rates in FSGS patients.

The most recent analyst rating on (TVTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.